Astal Laboratories Ltd

Dematerialisation processing and related actions

• Dematerialisation requests for quarter ended September 2026 were processed and confirmed to depositories.
• Securities dematerialised have been listed on the exchanges where previously listed.
• Physical certificates received for dematerialisation were mutilated and cancelled after verification.
• Depository name substituted as registered owner in the records within 15 days.

Astal Laboratories Limited trading window closed from 01 October 2026 till 48 hours after the declaration of the unaudited financial results for the quarter & half year ended on 30 September 2026.

Governance and audit appointments

• Board approves M/s Avnesh Jain & Co. as Cost Auditor for FY 2026-27.
• Cost Auditor appointment effective 28 September 2026 for FY 2026-27.
• Board approves M/s Khandelwal & Co. as Secretarial Auditor for FY 2026-27.
• Board appoints Mr Balayogiswara Rao Pedinti as finance professional for FY 2026-27.
• Disclosures of relationships between directors for these appointments Not Applicable.

Company Secretary appointment

• Appointment of Kedia as Company Secretary of Astal Laboratories Limited effective 28 September 2026.

AGM Details

• Date, time and mode: 29 September 2026, 1:30 PM IST via VC/OAVM.

Resolutions

• Ordinary: Adopt standalone financial statements for the year ended 31 March 2026.
• Ordinary: Adopt consolidated financial statements for the year ended 31 March 2026.
• Ordinary: Re-appointment of Maggidi Venkatesh, Non-Executive Director, by rotation.

Director Changes

• Maggidi Venkatesh re-appointed as Non-Executive Director by rotation.

Voting Details

• Mode of voting: E-Voting for all resolutions.
• Voting results to be disseminated within 48 hours.

Code type and regulation

• Code of Conduct under SEBI PIT Regulations, 2015 governs insider trading.

Promoter disclosures received

• Promoter ACESO RESEARCH LABS LLP submitted Form C for share purchases (10 Sep 2026).

Declaration filed

• Declaration under Regulation 7(2) for purchase of equity shares enclosed.

Recordkeeping and reporting

• Disclosures recorded by Corporate Secretary and shared with BSE.

Roles and responsibilities

• Company Secretary & Compliance Officer oversee insider-trading disclosures.

AGM notice and report access

• AGM 33rd scheduled for Sep 29, 2026 at 1:30 PM IST via VC/OAVM.
• Annual Report FY2025-26 and AGM Notice accessible on astallabs.com.
• Book closure from Sep 23 to Sep 29, 2026.
• Voting cut-off date Sep 22, 2026.
• e-voting opens Sep 26, 2026; ends Sep 29, 2026 at 5:00 PM.
• Notice accessible via provided web link and QR code.
• Annual Report available on CDSL and BSE websites.
• Physical copies available on request to investor relations.
• KYC update reminder for SEBI circular; PAN, contact, bank details required.
• Dematerialization of physical securities urged; update with DP or RTA.

AGM Details

• AGM scheduled for 29 September 2026 at 01:30 PM.
• Mode: VC/OAVM.
• Record date: 22 September 2026.
• Register of Members closed 23-29 September 2026.

Key Ordinary Resolutions

• Adopt standalone financial statements for FY2025-26.
• Adopt consolidated financial statements for FY2025-26.
• Re-appointment of director retiring by rotation.

Director Changes

• Director retire-by-rotation; eligible for re-appointment.

Financial highlights

• Standalone revenue from operations: ₹15,599.53 lakh for FY2025-26.
• Standalone PAT: ₹811.55 lakh.
• Consolidated revenue from operations: ₹25,014.81 lakh.
• Consolidated PAT: ₹1,470.94 lakh.
• Revenue growth (Standalone YoY): 142.88%.
• Standalone PAT YoY: -9.07%.
• Dividend declared for FY2025-26: none.
• Consolidated results include Sriven Pharmachem from 14-Jan-2026.

Acquisition & growth

• Sriven Pharmachem India Pvt Ltd acquired; 100% stake.
• Acquisition date: 14-Jan-2026.
• Goodwill recognized: ₹20,320.17 lakh.
• Consideration: ₹27,716.95 lakh; Net assets: ₹7,396.98 lakh.
• Equity issued: 3,04,25,632 shares at ₹81 premium.
• Warrants converted: 19,59,930 shares; ₹587.98 lakh received.
• Equity share capital increased to ₹4,223.12 lakh.
• Acquiree wholly owned; consolidation from acquisition date.

Capital structure & liquidity

• Standalone long-term borrowings: ₹36.59 lakh; current ₹1,159.20 lakh.
• Consolidated long-term borrowings: ₹1,864.15 lakh; current ₹3,044.10 lakh.
• Total borrowings: standalone ₹1,195.78 lakh; consolidated ₹4,908.25 lakh.
• Standalone cash and cash equivalents: ₹69.60 lakh.
• Consolidated cash and cash equivalents: ₹70.27 lakh.
• Equity capital stands at ₹4,223.12 lakh.

Subsidiary & consolidation

• Sriven Pharmachem India Pvt Ltd is a wholly owned subsidiary.
• Consolidated FS include Sriven from 14-Jan-2026.
• Goodwill from acquisition: ₹20,320.17 lakh.
• Acquisition comprised 30,458,187 equity shares; 3,04,25,632 via swap.
• Consolidation eliminates intragroup balances.

Governance & CSR

• Board: 7 directors; 4 independent; one Whole Time Director.
• Independent Directors meeting on 14-Feb-2026.
• EPS: standalone basic ₹4.76; diluted ₹4.31.
• EPS: consolidated basic ₹8.62; diluted ₹7.81.
• CSR spend ₹8.73 lakh; average net profit ₹43.65 crore.
• Dividend policy: no dividend.

Outlook & risks

• Outlook remains positive; focus on API manufacturing and R&D.
• Strategic acquisitions to expand global footprint.
• Risks include regulatory compliance, supply chain, pricing, and FX movements.